Polyclonal Antibody to Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL)
| Code | Size | Price |
|---|
| PAA855Ra01-20ul | 20ul | £86.00 |
Quantity:
| PAA855Ra01-100ul | 100ul | £158.00 |
Quantity:
| PAA855Ra01-200ul | 200ul | £214.00 |
Quantity:
| PAA855Ra01-1ml | 1ml | £488.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CD254; TNFSF11; ODF; OPGL; TRANCE; HRANKL2; SOdf; Tumor Necrosis Factor(ligand)superfamily Member 11; TNF-related activation-induced cytokine
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Receptor Activator Of Nuclear Factor Kappa B Ligand
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-3ug/mL;<br/>Immunohistochemistry: 5-30ug/mL;<br/>Immunocytochemistry: 5-30ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Receptor Activator Of Nuclear Factor Kappa B Ligand (RANkL) | RPA855Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||